Malignant Hyperthermia and Central Core Disease

[1]  A. Kunselman,et al.  The Sensitivity and Specificity of the Caffeine‐Halothane Contracture Test: A Report from the North American Malignant Hyperthermia Registry , 1998 .

[2]  D. Maclennan,et al.  Bayesian Modeling of Muscle Biopsy Contracture Testing for Malignant Hyperthermia Susceptibility , 1998, Anesthesiology.

[3]  F. Lehmann-Horn,et al.  In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low‐risk subjects , 1997, Acta anaesthesiologica Scandinavica.

[4]  P Stieglitz,et al.  Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. , 1997, American journal of human genetics.

[5]  C. van Broeckhoven,et al.  A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees. , 1997, Human molecular genetics.

[6]  A. Stewart,et al.  The G1021A substitution in the RYR1 gene does not cosegregate with malignant hyperthermia susceptibility in a British pedigree. , 1997, American journal of human genetics.

[7]  M. Phillips,et al.  The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene. , 1996, Genomics.

[8]  D. Maclennan.  Discordance between phenotype and genotype in malignant hyperthermia. , 1995, Current opinion in neurology.

[9]  A. George,et al.  Masseter Muscle Rigidity Associated with Glycine1306-to- Alanine Mutation in the Adult Muscle Sodium Channel α-Subunit Gene , 1995 .

[10]  P. Iaizzo,et al.  Anesthetic complications in muscle disorders. , 1995, Anesthesiology.

[11]  F. Lehmann-Horn,et al.  Skeletal muscle DHP receptor mutations alter calcium currents in human hypokalaemic periodic paralysis myotubes. , 1995, The Journal of physiology.

[12]  C. van Broeckhoven,et al.  Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. , 1995, American journal of human genetics.

[13]  R. Ophoff,et al.  Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families. , 1995, American journal of human genetics.

[14]  F. Lehmann-Horn,et al.  Altered calcium currents in human hypokalemic periodic paralysis myotubes expressing mutant L-type calcium channels. , 1995, Society of General Physiologists series.

[15]  M. Phillips,et al.  The substitution of Arg for Gly2433 in the human skeletal muscle ryanodine receptor is associated with malignant hyperthermia. , 1994, Human molecular genetics.

[16]  M. Lehane,et al.  Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees. , 1994, Human molecular genetics.

[17]  J. Weissenbach,et al.  A calcium channel mutation causing hypokalemic periodic paralysis. , 1994, Human molecular genetics.

[18]  S. Scherer,et al.  Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. , 1994, Human molecular genetics.

[19]  A. Localio,et al.  A Clinical Grading Scale to Predict Malignant Hyperthermia Susceptibility , 1994, Anesthesiology.

[20]  J. Weissenbach,et al.  Mapping of the hypokalaemic periodic paralysis (HypoPP) locus to chromosome 1q31–32 in three European families , 1994, Nature Genetics.

[21]  A. Stewart,et al.  Genetic mapping of the β1- and γ-subunits of the human skeletal muscle L-type voltage-dependent calcium channel on chromosome 17q and exclusion as candidate genes for malignant hyperthermia susceptibility , 1993 .

[22]  Thomas Deufel,et al.  Exclusion of malignant hyperthermia susceptibility (MHS) from a putative MHS2 locus on chromosome 17q and of the α1, β1, and γ subunits of the dihydropyridine receptor calcium channel as candidates for the molecular defect , 1993 .

[23]  M. Leppert,et al.  Sodium channel mutations in paramyotonia congenita and hyperkalemic periodic paralysis , 1993, Annals of neurology.

[24]  F. Couch,et al.  Refined genetic localization for central core disease. , 1993, American journal of human genetics.

[25]  K. Johnson,et al.  The genetics of malignant hyperthermia. , 1993, Journal of medical genetics.

[26]  A. Olckers,et al.  Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. , 1992, Genomics.

[27]  A. Olckers,et al.  Adult muscle sodium channel alpha-subunit is a gene candidate for malignant hyperthermia susceptibility. , 1992, Genomics.

[28]  J. Landis,et al.  Prediction Of Malignant Hyperthermia Susceptibility In Man: Improving Sensitivity Of The Caffeine Halothane Contracture Test , 1992 .

[29]  N. Pollock,et al.  Propofol is a ‘Safe’ Anaesthetic Agent in Malignant Hyperthermia Susceptible Patients , 1992 .

[30]  M. Phillips,et al.  The role of the skeletal muscle ryanodine receptor gene in malignant hyperthermia. , 1992, Symposia of the Society for Experimental Biology.

[31]  P. Lomax,et al.  Thermoregulation : pathology, pharmacology, and therapy , 1991 .

[32]  P. Iaizzo,et al.  Are myotonias and periodic paralyses associated with susceptibility to malignant hyperthermia? , 1990, British journal of anaesthesia.

[33]  M. Phillips,et al.  Molecular cloning of cDNA encoding human and rabbit forms of the Ca2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. , 1990, The Journal of biological chemistry.

[34]  M. G. Larach.  Standardization of the Caffeine Halothane Muscle Contracture Test , 1989, Anesthesia and analgesia.

[35]  S. Fleischer,et al.  Biochemistry and biophysics of excitation-contraction coupling. , 1989, Annual review of biophysics and biophysical chemistry.

[36]  J. Lerman.  Controversies in paediatric anaesthesia , 1988, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[37]  A. Brownell.  Malignant hyperthermia: relationship to other diseases. , 1988, British journal of anaesthesia.

[38]  A. Shuaib,et al.  Central Core Disease: CLINICAL FEATURES IN 13 PATIENTS , 1987, Medicine.

[39]  A. Perel,et al.  HIGH FREQUENCY CONVENTIONAL VENTILATION ALSO MINIMIZES RESPIRATORY-RELATED MOVEMENT OF KIDNEY STONES DURING ESWL IS IT, HOWEVER, INDICATED? , 1986 .

[40]  H. Rosenberg,et al.  Masseter Muscle Rigidity and Malignant Hyperthermia Susceptibility , 1986, Anesthesia and analgesia.

[41]  B. Britt.  Malignant Hyperthermia: A Review , 1982 .

[42]  G. Harrison.  Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. , 1975, British journal of anaesthesia.

[43]  M. Denborough,et al.  Anesthetic-induced malignant hyperpyrexia in children. , 1973, The Journal of pediatrics.

[44]  Ellis Fr,et al.  A new screening test for susceptibility to malignant hyperpyrexia. , 1973 .

[45]  B. Britt,et al.  Metabolic error of muscle metabolism after recovery from malignant hyperthermia. , 1970, Lancet.

[46]  M. Berman,et al.  Changes underlying Halothane-induced Malignant Hyperpyrexia in Landrace Pigs , 1970, Nature.

[47]  B. Britt,et al.  HYPERRIGIDITY AND HYPERTHERMIA ASSOCIATED WITH ANESTHESIA , 1968, Annals of the New York Academy of Sciences.

[48]  L W Hall,et al.  Unusual reaction to suxamethonium chloride. , 1966, British medical journal.

[49]  P. A. Maplestone,et al.  ANAESTHETIC DEATHS IN A FAMILY , 1962, British journal of anaesthesia.

[50]  V. Dubowitz,et al.  Oxidative enzymes and phosphorylase in central-core disease of muscle. , 1960, Lancet.

[51]  G. Shy,et al.  A new congenital non-progressive myopathy. , 1956, Brain : a journal of neurology.